Shaping Humanity's Cognitive Future
J.L. Mee is a leading innovator in the emerging field of human cognitive enhancement.
He is the founder of Cognigenics, Inc., a pioneering neurotech company developing precision gene therapies to improve mental health and cognitive performance.]
Together with co-inventors Dr. Dean Radin and Dr. James Fallon, Mr. Mee formulated the world's first cognitive neuroengineering systems architecture—a multidisciplinary framework applying cognitive genetics to expand awareness, increase mental clarity, and optimize neural function.
Earlier in his career, Mr. Mee led major R&D initiatives in the computer industry. He brings a deep engineering rigor and the discipline of building complex, commercially successful systems to the evolution of human consciousness.
The new science of cognitive neuroengineering which Cognigenics is developing reflects a synthesis of his management acumen, engineering expertise, scientific work and decades of inquiry into the nature of human potential.
In 2017, Mee discovered a master control switch for consciousness in the human genome.
He invented scientific methods for modifying this gene to improve cognition and, together with co-founder Dr. Dean Radin, built a top-notch team of neuroscientists and executives, raised angel and venture financing and developed a product.
The company conducted 25 preclinical research experiments which conclusively demonstrated the product's efficacy in animal models; reducing anxiety by 34% and improving memory by 94%.
The results were published in top-tier scientific journals, and the research is proceeding towards first in-human use.Th
The ability to form memories is largely a function of attention.
In neuroscience, attention in mice is regarded as a proxy for awareness in humans.
Thus, we may be at the threshold of creating new states of consciousness.
The company's technology has been validated:
● in multiple indications (1)
● in multiple species (2)
● using multiple gene editors (3)
● on multiple targets (4)
● for multiple genes (5).
Results have been
● replicated across multiple behavioral models (6) and
● validated in multiple diagnostic assays (7)
● on multiple neuron types (8).
Innovation
J.L. Mee holds multiple patents pending on genetic engineering methods for enhancing human cognition. These discoveries form the enabling technology for expanding human cognitive capital to meet the challenges of the 21st Century; boosting mental health, attention, focus, creativity, memory and mental acuity.
With co-inventors Dr. Dean Radin and Dr. James Fallon, Mr. Mee developed a revolutionary cognitive neuroengineering platform systems architecture to alleviate neurological conditions in specific brain areas.
● Neurological disorders: The platform will enable dozens of clinical applications for addressing a wide spectrum of neurological conditions without the side effects of pharmaceuticals. Treatable conditions include stress, anxiety, depression, obsessive-compulsive disorder (OCD), attention deficit disorder (ADD), mild cognitive impairment (MCI) and memory issues. These disorders typically involve imbalances in various brain regions, and their behavioral and cognitive effects can be mitigated by normalizing the unbalanced areas.
● Cognitive enrichment: The system can also be used to improve memory, reverse cognitive decline, decrease inattention, reduce mind-wandering, lower craving, sharpen mental focus, increase concentration, and foster emotional balance.
● Platform technology: Due to its breadth of application, this technology can form the bedrock for a cognitive treatment and enhancement ecosystem which can have far-reaching effects on human mental health, cognitive capacity and overall well-being.
Mission
Cognigenics is developing a 21st Century mental health science based upon the latest genetic engineering technologies. The firm builds shareholder value by expanding its portfolio of intellectual property through innovative research and experimentation.
Conclusions
The advent of next-generation mental health technology represents a defining moment in the progress of medicine. Visionary leadership is required to achieve the full promise of cognitive neuroengineering, and progressive business, financial and engineering leaders are collaborating to maximize the potential of this transformative technology.